Newton vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI phone platform for dental practices handling patient scheduling, insurance verification, and reactivation campaigns; $3.8M seed from YC serving DSOs competing with Weave and NexHealth.
About
Newton is an AI-powered phone and patient communication platform for dental practices and dental service organizations (DSOs) — deploying AI voice agents that handle inbound patient calls (appointment scheduling, insurance verification questions, appointment reminders) and outbound patient reactivation campaigns that identify and contact overdue patients, automating the front-desk phone work that consumes significant staff time at dental offices. Founded in 2023 in San Francisco and a Y Combinator W24 graduate, Newton raised $3.8 million in seed funding in October 2025 from Y Combinator, Twenty Two Ventures, Transpose Platform, and Phosphor Capital.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.